Analyst Price Targets — LBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 1:13 pm | — | Craig-Hallum | $36.00 | $24.69 | TheFly | Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy |
| March 27, 2026 10:16 am | — | Stifel Nicolaus | $40.00 | $23.84 | TheFly | LB Pharmaceuticals price target raised to $40 from $35 at Stifel |
| January 9, 2026 9:26 am | — | Roth Capital | $31.00 | $20.80 | TheFly | LB Pharmaceuticals initiated with a Buy at Roth Capital |
| December 11, 2025 12:23 pm | — | Stifel Nicolaus | $35.00 | $21.36 | TheFly | LB Pharmaceuticals price target raised to $35 from $27 at Stifel |
| October 6, 2025 10:15 am | — | Leerink Partners | $34.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with an Outperform at Leerink |
| October 6, 2025 9:15 am | — | Stifel Nicolaus | $27.00 | $15.05 | TheFly | LB Pharmaceuticals initiated with a Buy at Stifel |
Latest News for LBRX
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual…
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trialin bipolar depression Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for theadjunctive treatment of major depressive disorder…
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LBRX.
Senate Trading
No Senate trades found for LBRX.
U.S. House Trading
No House trades found for LBRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.